Immunology-focused biotech startup Gossamer Bio has its market debut, with a lead drug candidate targeting moderate-to-severe asthma.
From Launch To IPO In 13 Months: Gossamer Bio CEO Says She’s Running Company Of Her Dreams
Immunology-focused biotech startup Gossamer Bio has its market debut, with a lead drug candidate targeting moderate-to-severe asthma.